Scientific breakthroughs across the cancer continuum: Research from the 2024 ASCO® Annual Meeting

Dr. Todd M. Bauer joined Tennessee Oncology and the Sarah Cannon Research Institute in 2012. He became heavily involved in the phase 1 clinical trial program and had the chance to be involved in the development of some exciting agents. Amongst those, he gave the first human dose of both larotrectinib and selpercatinib, as well as being involved in the opening cohort of lorlatinib and capmatinib. While he is proud of his involvement in those drugs and all those he has helped develop, his true passion is patient care, which prompted a transition to full-time general medical oncology and hematology. He loves caring for his patients on a one-on-one basis. He now supports the Greco-Hainsworth Centers for Research, a newly founded clinical research program in Nashville. He also enjoys the chance to help educate colleagues about new and emerging paradigms of care in the oncology world. 

 Profile

Dr. Amy L. Cummings is Assistant Professor of Medicine in the Department of Medicine, Hematology/Oncology at the David Geffen School of Medicine. Dr. Cummings is a thoracic oncologist, physician-scientist, and clinical trialist. Her academic interests include early-stage lung cancer, precision medicine, and equitable care. She currently serves as the UCLA Health Jonsson Comprehensive Cancer Center's Director of Justice, Equity, Diversity and Inclusion (JEDI) and Data Chair for the University of California Lung Cancer Consortium.

 LinkedIn

Dr. Mothaffar Rimawi is a board-certified oncologist with additional training in breast cancer clinical care and translational research. He is the Associate Director for Clinical Affairs and Executive Medical Director of the Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine and Baylor St Luke’s Medical Center. He is a funded investigator focused on translation of preclinical discoveries to the clinic by designing and conducting biologically rational, biospecimen-intense targeted therapy clinical trials. Dr. Rimawi studies biomarkers of response and resistance on tumor samples from these trials samples to help elucidate mechanisms of therapeutic resistance. His overall research focus is on precision medicine approaches to breast cancer patients and developing a treatment de-escalation strategy to spare cancer patients the unnecessary toxicity and cost, when possible, without compromising outcomes. His work helped advance dual HER2 inhibition, concurrent targeting of ER with HER2, better understanding of endocrine therapy resistance, and treatment de-escalation in HER2-positive breast cancer. Dr. Rimawi serves on multiple national clinical research leadership committees. He is Vice Chair of the Breast Committee of the NRG Oncology Group, and co-Chair the HER2 Working group of the Translational Breast Cancer Symposium (TBCRC).

Dr. Ezra Cohen is a leading medical oncologist and cancer researcher who brings a unique combination of extensive clinical and research experience to Tempus’ leadership team. He was most recently the Chief of the Division of Hematology-Oncology as well as the Associate Director of Clinical Science at UC San Diego (UCSD) Moores Cancer Center. Dr. Cohen also led the Precision Immunotherapy Clinic and co-directed the San Diego Center for Precision Immunotherapy at UCSD. Before UCSD, Dr. Cohen spent 15 years at the University of Chicago, where he was the co-director of the Head and Neck Cancer Program as well as Hematology/Oncology Fellowship Program Director.